Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets

Mersana Therapeutics Inc (NASDAQ:MRSN) has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ), to discover antibody-drug conjugates (ADCs) for three targets.

  • Janssen unit is doling out $40 million upfront and more than $1 billion in potential milestone payments for ADCs spanning three targets. 
  • The pair will work together to research target candidates during preclinical development. J&J's biotech unit will provide proprietary antibodies, and Mersana will contribute its Dolasynthen platform to help find the new ADC product candidates. 
  • After preclinical work is completed, Janssen will handle the therapies' clinical development and commercialization. Mersana will receive mid-single-digit to low-double-digit percentage royalties on global sales should any of them reach the market. 
  • Mersana's lead ADC, upifitamab rilsodotin, is currently being tested in a Phase 3 trial as maintenance therapy for recurrent, platinum-sensitive ovarian cancer. 
  • Related: Why Are Mersana Therapeutics Shares Trading Lower On Friday?.
  • Price Action: MRSN shares are up 2.10% at $4.38 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.